Key facts
- This page summarizes Thomas Catinazzo's Form 4 filing for Relay Therapeutics, Inc. (RLAY).
- 10 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 24 Jun 2026, 16:09.
Thomas Catinazzo - 22 Jun 2026 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- RLAY
- Reported as of
- 22 Jun 2026
- Net transaction value
- -$3,176,865
- SEC form
- 4
- Accepted by SEC
- 24 Jun 2026, 16:09:57 UTC
- Prior SEC filing
- 14 May 2026
- Next SEC filing
- 08 Jul 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Soo-Yeun Lim, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Thomas Catinazzo filed Form 4 for Relay Therapeutics, Inc. (RLAY) on 24 Jun 2026.
Change
- Previous filing in this sequence was filed on 14 May 2026.
- Current net transaction value: -$3,176,865.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001818261
Primary reporting owner
Catinazzo Thomas
- Relationship
- Chief Financial Officer
- Address
- C/O RELAY THERAPEUTICS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE
- Signature
- /s/ Soo-Yeun Lim, as Attorney-in-Fact
- Signature date
- 24 Jun 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RLAY
transaction
Common Stock
Sale
- Transaction value
- $301,366
- Shares
- -17,717
- Change %
- -9.1%
- Price
- $17.01
- Shares after
- 177,461
- Date
- 22 Jun 2026
- Ownership
- Direct
- Footnotes
- F1, F2, F3
RLAY
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +56,323
- Change %
- +32%
- Price
- $5.04*
- Shares after
- 233,784
- Date
- 22 Jun 2026
- Ownership
- Direct
- Footnotes
- F1, F3
RLAY
transaction
Common Stock
Sale
- Transaction value
- $955,801
- Shares
- -56,323
- Change %
- -24%
- Price
- $16.97
- Shares after
- 177,461
- Date
- 22 Jun 2026
- Ownership
- Direct
- Footnotes
- F1, F3, F4
RLAY
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +61,563
- Change %
- +35%
- Price
- $5.22*
- Shares after
- 239,024
- Date
- 22 Jun 2026
- Ownership
- Direct
- Footnotes
- F1, F3
RLAY
transaction
Common Stock
Sale
- Transaction value
- $1,044,724
- Shares
- -61,563
- Change %
- -26%
- Price
- $16.97
- Shares after
- 177,461
- Date
- 22 Jun 2026
- Ownership
- Direct
- Footnotes
- F1, F3, F4
RLAY
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +51,560
- Change %
- +29%
- Price
- $4.45*
- Shares after
- 229,021
- Date
- 22 Jun 2026
- Ownership
- Direct
- Footnotes
- F1, F3
RLAY
transaction
Common Stock
Sale
- Transaction value
- $874,973
- Shares
- -51,560
- Change %
- -23%
- Price
- $16.97
- Shares after
- 177,461
- Date
- 22 Jun 2026
- Ownership
- Direct
- Footnotes
- F1, F3, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RLAY
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -56,323
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 22 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 56,323
- Exercise price
- $5.04
- Footnotes
- F1, F5
RLAY
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -61,563
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 22 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 61,563
- Exercise price
- $5.22
- Footnotes
- F1, F6
RLAY
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -51,560
- Change %
- -19%
- Price
- $0.000000*
- Shares after
- 223,440
- Date
- 22 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 51,560
- Exercise price
- $4.45
- Footnotes
- F1, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 7 footnotes
Footnote F1
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.
Footnote F2
This transaction was executed in multiple trades at prices ranging from $16.38 to $17.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Footnote F3
Includes 9,807 shares underlying restricted stock units.
Footnote F4
This transaction was executed in multiple trades at prices ranging from $16.15 to $17.39. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Footnote F5
The shares underlying this stock option vested in sixteen (16) equal quarterly installments following the vesting commencement date of April 23, 2019.
Footnote F6
On March 2, 2020, the reporting person was granted an option to purchase 63,363 shares of common stock, subject to determination by the Board of Directors of the Issuer (the "Board") that the Issuer met, in whole or in part, certain milestones (the "2020 Option Grant Criteria"). On June 23, 2020, the Board determined that the 2020 Option Grant Criteria related to 25% of the option had been achieved, and the shares underlying 25% of this option, or 15,841 shares, commenced vesting in sixteen (16) equal quarterly installments following September 23, 2020. On December 11, 2020, the Board determined that the 2020 Option Grant Criteria related to the remaining 75% of the option had been achieved. The shares underlying 75% of this option, or 47,522 shares, vested in sixteen (16) equal quarterly installments following March 11, 2021.
Footnote F7
The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments after January 10, 2025, subject to the reporting person's continued service with the Issuer through each vesting date.